What happened
Nolla Health launched a pilot program in Utah, becoming the first US entity authorized by a state regulator to issue initial prescriptions using AI. The Nolla Derm app allows Utah residents aged 18 and older to receive personalized acne treatment plans and prescriptions after a digital intake process, including a face scan, without an in-person office visit. The service costs $4.99 per month and operates under strict safety developed with the Utah Office of Artificial Intelligence Policy.
Nolla Health has secured authorization from the Utah Office of Artificial Intelligence Policy to operate the first US pilot allowing AI to issue initial prescriptions. The program focuses specifically on acne treatment, a condition described as well-understood and low-risk. This authorization distinguishes the pilot from previous AI healthcare applications that were limited to prescription refills.
The service is available to Utah residents aged 18 and older through the Nolla Derm app. The process involves identity verification, informed consent, a short intake questionnaire, and a five-angle face scan. This digital workflow generates a personalized treatment plan and, if appropriate, an initial prescription within 10 to 15 minutes. The cost is $4.99 per month, significantly lower than the up to $300 cost of an in-person dermatologist visit.
The pilot operates under strict clinical . The AI selects from pre-approved topical treatment plans based on structured clinical inputs and face scan assessments. It does not have a free-text interface, preventing it from deviating from approved protocols. Patients with severe acne, pregnancy, or other conditions outside the pilot scope are referred to licensed physicians or in-person care. Licensed clinicians can be contacted by patients at any time, and messages are answered by humans, not AI.
The program is structured in stages with specific safety targets. Stage one runs for at least four weeks, and stage two for at least eight. Progression requires meeting a 95% agreement rate with physicians and zero serious adverse events, along with written approval from the state. Nolla Health reports that licensed clinicians agree with the AI's treatment recommendations in 96% of real-world cases, with discrepancies limited to minor adjustments like topical strength.
Source details: nollahealth.com ↗
Why it matters
This pilot marks a significant regulatory milestone for AI in healthcare, moving beyond refills to initial diagnostic and prescribing authority. It addresses access gaps in healthcare deserts where dermatologist availability is low and wait times are long. By restricting the AI to pre-approved topical plans for a well-understood condition like acne, the pilot aims to balance innovation with patient safety, setting a precedent for how states may regulate autonomous AI clinical decisions.
This development represents a concrete shift in AI policy and deployment, moving from advisory or refill-only roles to direct clinical decision-making for initial prescriptions. It highlights a new regulatory pathway for AI in healthcare, specifically in states like Utah that are actively engaging with AI policy offices.
The pilot addresses a documented healthcare access issue. With over 80% of US counties classified as healthcare deserts and long wait times for dermatologists, AI-driven initial prescriptions could provide timely care for common conditions. The low cost of $4.99 per month aims to remove financial barriers that prevent patients from seeking treatment.
The strict , including the limitation to pre-approved topical plans and the exclusion of complex cases, suggest a cautious approach to in medicine. This model may serve as a template for other states or healthcare providers looking to integrate AI into clinical workflows while maintaining high safety standards.
Interactive Mechanism: How It Actually Works
Explore the underlying technology behind this development interactively.
crm_get_transaction(id='4092').Why can ethical evaluation not be reduced to one model score?
What to watch next
Monitor the pilot's safety metrics, specifically the 95% physician agreement rate and zero serious adverse events target, which are required for expansion. Watch for regulatory responses from other states and the FDA regarding AI-issued initial prescriptions. Observe whether the model expands to other conditions or states after the initial four-week stage.
The success of the pilot will depend on meeting the stated safety targets, particularly the 95% physician agreement rate and zero serious adverse events. Failure to meet these benchmarks could halt expansion or lead to regulatory scrutiny.
Regulatory developments in other states and at the federal level will be crucial. If other states follow Utah's lead, it could create a patchwork of AI healthcare regulations. The FDA's stance on AI-issued initial prescriptions will also influence the broader adoption of such technologies.
Expansion of the pilot to other conditions or geographic areas will indicate the scalability of the model. Currently, the app is available in 44 states under clinician guidance, but the AI-issued prescription feature is limited to the Utah pilot.